Histide AG, a Swiss biotech company developing a new class of non-mutagenic extracellular technology, closed a CHF4.5M Series A financing round.
The round was led by Parter Capital Group AG, Switzerland, and a group of private investors.
The company intends to use the funds to further expand its IP licensing pipeline and clinical development of its Recoding MoleculesTM.
Founded in 2014 by Florian Kemmerich, CEO of Histide and Partner, Life Science, at Parter Capital Group, Histide has created Recoding Therapeutics™, a platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.